Table 1.
Reviewed patients’ characteristics and clinical manifestations (n = 92).
Variables | Number (% except for age) |
---|---|
Median age (range, years) | 66 (16–92) |
Male gender (%) | 50 (54) |
Smoking history | |
Current smoker | 5 (5) |
Ex-smoker | 17 (18) |
Never smoker | 36 (39) |
Unknown | 34 (37) |
Infectious routes | |
Cruise ship | 25 (27) |
Music club, bar, night club | 3 (3) |
Travel history | 6 (7) |
Nursing home | 10 (11) |
Sick contact | 28 (30) |
Other | 2 (2) |
Unknown | 21 (23) |
Underlying diseases (n = 90) | |
Any | 60 (67) |
Heart disease | 7 (8) |
Chronic respiratory disease | 10 (11) |
Diabetes mellitus | 18 (20) |
Malignancy | 11 (12) |
Chronic kidney disease | 4 (4) |
Chronic hepatic disease | 4 (4) |
Hypertension | 32 (36) |
Hyperlipidemia | 14 (16) |
Cerebrovascular disease | 8 (9) |
Collagen vascular disease | 4 (4) |
Symptoms on diagnosis | |
Fever (≧37.5 °C) | 66 (72) |
Cough | 37 (40) |
Sputum | 4 (4) |
Sorethroat | 15 (16) |
Runny nose | 9 (10) |
Dyspnea | 13 (14) |
General fatigue | 33 (36) |
Headache | 5 (5) |
Anorexia | 10 (11) |
Diarrhea | 10 (11) |
Stomachache | 2 (2) |
Consciousness disturbance | 2 (2) |
Nausea/vomit | 5 (5) |
Headache | 13 (14) |
Taste disorder | 5 (5) |
Olfactory disorder | 3 (3) |
Respiratory rate ≧22 (/min) | 10/69 (14) |
Respiratory failure [SpO2<90% (room air)] | 11/90 (12) |
Fine crackles on ausculations | 10/68 (15) |
Treatment (n = 82) | |
Prednisolone | 16 (20) |
Hydroxychloroquine | 11 (13) |
Lopinavir/ritonavir, | 28 (34) |
Macrolides | 16 (20) |
Neuraminidase inhibitors | 7 (9) |
Ciclesonide, | 26 (32) |
Camostat | 5 (6) |
Nafamostat | 2 (2) |
Favipiravir | 18 (22) |
Baloxavir | 2 (2) |
Kampo medicine | 6 (7) |
Sivelestat | 3 (4) |
Hemodialysis | 2 (2) |
Intravenous immunoglobulin | 3 (4) |
Intratracheal intubation and mechanical ventilation | 14 (17) |
Outcome∗ (n = 65) | |
Survival | 61 (94) |
Death | 4 (6) |
SpO2, oxygen saturation.
Twenty-seven patients moved to other institutes or under treatment.